NCT01677689View on ClinicalTrials.gov

Study to Investigate the Efficacy and Safety of Apomivir®

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

May 31, 2026

Primary Completion Date

May 31, 2027

Study Completion Date

December 31, 2027

Conditions
Influenza
Interventions
DRUG

Apomivir®

Study Group: Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.

DRUG

Placebo

Control Group: Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.

Trial Locations (1)

40447

China Medical University Hospital, Taichung

All Listed Sponsors
lead

Far East Bio-Tec Co., Ltd

INDUSTRY